Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tick-borne encephalitis inactivated vaccine
- Development stage
- Approved
- Lead developer
- Immuno
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Tick-borne encephalitis inactivated vaccine is a biologic vaccine used to prevent tick-borne encephalitis (TBE), an acute viral infection of the central nervous system caused by the tick-borne encephalitis virus (TBEV), a member of the Flavivirus genus. The vaccine is produced by cultivating TBEV (commonly using strains such as "森张株" in China or Neudoerfl strain in Europe) on primary hamster kidney cells or Vero cells, followed by virus harvest, chemical inactivation (e.g., with formaldehyde), purification, and formulation with stabilizers and adjuvants such as aluminum hydroxide. The resulting product is a milky suspension containing inactivated whole TBE virus particles. Upon intramuscular injection, it stimulates the immune system to produce neutralizing antibodies against TBEV, providing protection against infection. It is recommended for individuals living in or traveling to endemic areas and laboratory workers at risk of exposure[1][2][3][7]. Major global brands include Ticovac (Pfizer) and FSME-Immun.
- Brand names
- TicovacFSME-Immun
- Other names
- 森林脑炎灭活疫苗Tick-borne Encephalitis Vaccine, Inactivated蜱传脑炎疫苗forest encephalitis vaccine
02
Targets
E (Tick-borne encephalitis virus envelope protein)
Beyond the preview
Go deeper on tick-borne encephalitis inactivated vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tick-borne encephalitis inactivated vaccine.